Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
FABP inhibitors bind fatty acid-binding proteins, small cytoplasmic carriers of long-chain fatty acids. Fatty acid-binding proteins (FABPs) are lipid chaperones with tissue-specific isoforms, such as FABP1 in liver, FABP3 in heart and FABP4 in adipocytes and macrophages. In 1996, mice lacking FABP4, then called adipocyte protein 2 (aP2), became obese on a high-fat diet without developing insulin resistance. BMS-309403 sodium is a salt of an FABP4 inhibitor that was studied in 2007 in mouse models of diabetes and atherosclerosis. HTS01037 and LDN-0088050 are listed as FABP4-directed inhibitors, while RO6806051 and FABP4/5-IN-6 inhibit both FABP4 and FABP5. FABP1-IN-1 and FABP-IN-2 extend the set to the liver and heart isoforms.
FABP4 Inhibitor is a cell-permeable biphenylazolo-oxyacetate that acts as a potent and selective inhibitor of adipocyte Fatty-Acid-Binding Protein (aFABP/aP2) by targeting its fatty acid-binding pocket (Ki = < 2 nM in a competitive binding assay using 1,8-ANS), while exhibiting much lower affinity for muscle and epidermal FABP's (Ki = 250 nM and 350 nM, respectively).
HTS01037 is an inhibitor of fatty acid binding; and a competitive antagonist of protein-protein interactions mediated by AFABP/aP2 with a Ki of 0.67 μM.
LDN 0088050 is selectivity adipocyte fatty acid binding protein (AFABP, FABP4) inhibitor with Ki values of 0.29 and 1.3 μM for FABP4 and FABP3, respectively. LDN 0088050 binds to FABP4 with a Kd of 2.05 μM.
FABP4/5-IN-6 is a potent inhibitor of fatty acid-binding proteins 4 and 5, with Ki values of 0.41 and 2.53 μM, respectively, and demonstrates low selectivity for FABP3 (Ki = 59.72 μM). This compound effectively reduces the secretion of pro-inflammatory cytokines such as MCP-1 and IL-6 in THP-1 macrophages stimulated by lipopolysaccharides (LPS), exhibiting notable anti-inflammatory properties. Additionally, FABP4/5-IN-6 mitigates LPS-induced liver injury, making it a valuable tool for investigating inflammation-related diseases. Its low hERG inhibition (LD50 > 2000 mg/kg) further supports its potential for in vivo studies.
Out of stock
All 3 sizes
BMS-309403 sodium is a selective inhibitor of adipocyte fatty acid binding protein 4 (FABP4), with a potent binding affinity characterized by Kis of
Synonyms: MF6
FABPs ligand 6, a selective inhibitor of fatty acid-binding proteins FABP5 and FABP7, exhibits KD values of 874 nM and 20 nM, respectively. This compound is instrumental in studying the role of FABPs in neurodegenerative diseases, particularly multiple sclerosis. Its inhibition of FABP5 and FABP7 provides valuable insights into their involvement in inflammatory pathways and neuronal function, making it a significant tool for related research applications.
FABP1-IN-1 is a selective inhibitor of fatty acid binding protein 1 (FABP1), exhibiting an IC50 of 4.46 μM. This compound is valuable for exploring the role of FABP1 in non-alcoholic steatohepatitis (NASH) research. Its inhibitory action aids in understanding metabolic disorders and potential therapeutic interventions targeting FABP1.
RO6806051 is a dual inhibitor of FABP4 and FABP5, demonstrating high specificity with Ki values of 0.011 μM for FABP4 and 0.086 μM for FABP5. This compound effectively modulates lipid metabolism and can play a significant role in studies related to obesity, diabetes, and other inflammation-related diseases. Its selective action provides a valuable tool for investigating the molecular pathways associated with these conditions.
FABP4/5-IN-5 is a selective inhibitor of Fatty Acid Binding Proteins 4 and 5 (FABP4/5), exhibiting IC50 values of 4.68 μM and 10.72 μM, respectively. This compound is significant in the study of metabolic disorders, particularly in relation to diabetes mellitus. Researchers can leverage FABP4/5-IN-5 to investigate the mechanisms of lipid metabolism and related pathologies.
FABP-IN-2 is a selective inhibitor of fatty acid-binding protein 3 (FABP3). It demonstrates potent inhibition of FABP3 and FABP4 with IC50 values of 1.16 μM and 4.27 μM, respectively. This reagent is valuable for investigating the role of FABP3 in various biological processes and may serve as a tool in studies related to metabolic disorders and cardiovascular diseases.
FABP4-IN-2 is a selective inhibitor of fatty acid-binding protein 4 (FABP4) with a Ki value of 0.51 μM, demonstrating its potency against this target. It exhibits significantly lower affinity for FABP3, with a Ki of 33.01 μM. This compound is applicable in the study of inflammation-related diseases, providing insights into the roles of FABP4 in metabolic processes and potential therapeutic strategies.
Out of stock
All 3 sizes
FABP4/5-IN-4 is a selective inhibitor of fatty acid binding proteins FABP4 and FABP5, exhibiting IC50 values of 3.78 μM and 5.72 μM, respectively. This compound is significant in the study of metabolic disorders, particularly in the context of diabetes mellitus, by modulating lipid metabolism and signaling pathways. It serves as a valuable tool for research aiming to elucidate the role of FABP4 and FABP5 in metabolic regulation.
